# Revolution Medicines (RVMD) — News

RVMD · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rvmd/news

## Recent headlines

- [Revolution Medicines' Rasonque gets positive EU CHMP opinion](https://www.ainvest.com/news/revolution-medicines-rasonque-positive-eu-chmp-opinion-2610) — AInvest Wire, Oct 15, 2026
  Revolution Medicines announced that its drug candidate, Rasonque, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation is a critical step toward potential marketing authorization in the European…
- [Revolution Medicines, Inc.: RBC raises target price to $260 from $259](https://www.ainvest.com/news/revolution-medicines-rbc-raises-target-price-260-259-2610) — AInvest Wire, Oct 14, 2026
  Revolution Medicines, Inc. (RVMD) has seen recent analyst activity that reflects a cautiously optimistic outlook for the clinical-stage biotechnology firm. On October 23, 2023, Oppenheimer maintained its "Outperform" rating for the company and raised its price target to $260 from $230, representing…
- [Refile-Publicis - Q3 net revenue EUR 3.81 bln, up 7.9% y/y (removes extraneous product codes)](https://www.ainvest.com/news/refile-publicis-q3-net-revenue-eur-3-81-bln-7-9-removes-extraneous-product-codes-2610) — AInvest Wire, Oct 13, 2026
  Publicis Group reported third-quarter net revenue of €3.81 billion, representing a 7.9% year-over-year increase, according to the company’s latest financial update. This growth reflects the firm’s ongoing performance in the advertising and marketing services sector, despite broader economic and…
- [LVMH CFO: Dior is positive year-to-date, Q3 is flat](https://www.ainvest.com/news/lvmh-cfo-dior-positive-year-date-q3-flat-2610) — AInvest Wire, Oct 12, 2026
- [LVMH CFO: Vuitton performance in Q3 was not very far from average](https://www.ainvest.com/news/lvmh-cfo-vuitton-performance-q3-average-2610) — AInvest Wire, Oct 12, 2026
  LVMH’s Chief Financial Officer noted in a recent update that the performance of the Vuitton brand in the third quarter was "not very far from average," according to internal assessments. This observation aligns with the company’s projected Q3 sales of 17.99 billion euros, which reflect a 1% organic…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).